Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(11):783; doi:10.1093/jnci/94.11.783
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Articles by Arnold, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wang, L.
Right arrow Articles by Arnold, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 11, 783, June 5, 2002
© 2002 Oxford University Press

Press Release

Studies Call for Quality Assurance in Selecting Candidates for Herceptin Trials

Linda Wang, Assistant News Editor, Katherine Arnold, News Editor

jncimedia@oupjournals.org

Two new studies suggest that local laboratories are not as accurate as central testing facilities at identifying women who are most likely to benefit from receiving trastuzumab (Herceptin) as adjuvant therapy for breast cancer. The findings appear in the June 5 issue of the Journal of the National Cancer Institute.

Past studies have suggested that trastuzumab may benefit breast cancer patients whose tumors overexpress, or produce too much, of the HER2 protein—a condition . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?